Sarah Tasian, MD, The Children’s Hospital of Philadelphia, Philadelphia, PA, discusses the clinical efficacy of azacitidine and venetoclax in pediatric patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). In this patient population, a complete remission (CR) rate of approximately 40% was observed, and Dr Tasian highlights the promise of this combination approach for the treatment of pediatric patients. This interview took place at the American Association for Cancer Research (AACR) Annual Meeting 2023 in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.